title: High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
abstract: OBJECTIVE
  The additive effect of ecabet sodium in combination with dual therapy on Helicobacter pylori eradication was evaluated.
  
  
  METHODS
  H. pylori-positive chronic gastritis patients were randomly assigned to one of the following three groups and medicated for 2 weeks. Group LA: dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.). Group LA1E: dual therapy plus ecabet sodium (1 g b.d.). Group LA2E: dual therapy plus ecabet sodium (2 g b.d.). Patients were evaluated 4 weeks after the cessation of treatment by culture and 13C-urea breath test.
  
  
  RESULTS
  Seventy-one patients (mean age, 56.6 years; range, 26-79 years; 40 males, 31 females) were enrolled in this prospective, single-blind study, and 68 completed the protocol. The eradication rates per protocol patient were 43% in group LA, 62% in group LA1E, and 79% in group LA2E, and those on the intention-to-treat basis were 42% in group LA, 57% in group LA1E and 79% in group LA2E. The eradication rate in group LA2E was significantly higher than group LA (P=0.032 in per protocol, P=0.022 in intention-to-treat). Adverse effects were observed in 10 patients in this study. There were no severe adverse effects caused by ecabet sodium.
  
  
  CONCLUSIONS
  High-dose ecabet sodium increases eradication rates of H. pylori in dual therapy with lansoprazole and amoxicillin.
authors.affiliation: Department of Gastroenterolgy and Hematology, Hokkaido University, Graduate School of Medicine, Sapporo, Japan. hikagaya@med.hokudai.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Kagaya
authors.forename: M
authors.initials: M
authors.lastname: Kato
authors.forename: Y
authors.initials: Y
authors.lastname: Komatsu
authors.forename: T
authors.initials: T
authors.lastname: Mizushima
authors.forename: M
authors.initials: M
authors.lastname: Sukegawa
authors.forename: K
authors.initials: K
authors.lastname: Nishikawa
authors.forename: K
authors.initials: K
authors.lastname: Hokari
authors.forename: H
authors.initials: H
authors.lastname: Takeda
authors.forename: T
authors.initials: T
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Asaka
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004224:Diterpenes / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use*; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D045784:Abietanes; D000897:Anti-Ulcer Agents; D004224:Diterpenes; D010406:Penicillins; D064747:Lansoprazole; C061681:ecabet; D000658:Amoxicillin; D009853:Omeprazole